Clinical Trial Update: Peptide Vaccine Targeting to Cancer Specific Antigen Combined With Anti-angiogenic Peptide Antigen in Treating Patients With Non-small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a cancer antigen-targeting peptide vaccine combined with an anti-angiogenic peptide antigen in non-small cell lung cancer has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• anti-angiogenic peptide antigen
• cancer antigen-targeting peptide vaccine

Snippet

Sponsor: Fukushima Medical University | Conditions: Non Small Cell Lung Cancer | Phase 1 | Status: COMPLETED